Cardiovascular disease (CVD) poses a highly significant health and economic burden
in Australia and worldwide, with the latest global burden of disease study identifying
cardiovascular disease as an “expanding threat to global health” [
[1]
]. Australian cardiovascular researchers are recognised internationally for their broad
expertise spanning from fundamental molecular and cellular biology, through innovative
bioengineering approaches, patient-focussed clinical trials, and impactful community
interventions for improved public health. However, funding challenges have resulted
in a fragmented research sector struggling to survive, let alone work together as
an effective national team with strategic leadership and collaboration. The Australian
Cardiovascular Alliance have successfully advocated for a federally supported Mission
for Cardiovascular Helath ($220 Million). A key element of success in their goal of
enhancing the CV health of Austrlaians, is partnering with industry.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Heart, Lung and CirculationAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the global burden of disease study 2017.Lancet. 2018; 392: 1736-1788
- The Australian cardiovascular alliance–towards an integrated whole-of-nation strategy to address our major health burden.Heart Lung Circ. 2019; 28: 198-203
- Healthcare expenditure and productivity cost savings resulting from increased intake of grain fibre in Australia.(Australia)2017
- Healthcare expenditure on cardiovascular diseases 2008-09.(Cat.No. CVD 65. Canberra)2014
- The economic value of Australia’s investment in health and medical research: reinforcing the evidence for exceptional returns. A paper commissioned by research Australia.(Sydney, NSW)2010
- Exceptional returns: the value of investing in health research & development in Australia.Report for the Australian society for medical research. 2003
- An analysis of original research contributions toward FDA-approved drugs.Drug Discov Today. 2015; 20: 1182-1187
- Cardiovascular drug discovery: a perspective from a research-based pharmaceutical company.Cold Spring Harb Perspect Med. 2014; 4a014092
Article info
Identification
Copyright
© 2019 Published by Elsevier B.V. on behalf of Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ).
